Atlas Trials

Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Clinical trial NCT04547088 · UNKNOWN

Trial details

NCT number
NCT04547088
Sponsor
Sun Yat-sen University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Nasopharyngeal Carcinoma
Start date
2020-09-01
Primary completion
2022-10-01
Enrollment
27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.